TCM
ALXN

Teza Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Teza Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,279
Closed -$463K – 568
2019
Q4 		$463K Sell
4,279
-4,631
-52% -$495K 0.13% 287
2019
Q3 		$873K Buy
+8,910
New +$1M 0.22% 149
2018
Q3 		– Sell
-8,361
Closed -$1.04M – 600
2018
Q2 		$1.04M Buy
+8,361
New +$977K 0.15% 206

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Teza Capital Management's ALXN Position: Q1 2020 in Review

Teza Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 4,279 shares — an estimated $463K sold.

Teza Capital Management first reported a position in ALXN in Q2 2018 and held it in 3 quarters. The position peaked at $1.04M in Q2 2018. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Teza Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Teza Capital Management sold 4,279 Alexion Pharmaceuticals shares in Q1 2020, an estimated $463K.
  • Teza Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Teza Capital Management's Alexion Pharmaceuticals position peaked at $1.04M in Q2 2018.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Teza Capital Management's 13F filing for Q1 2020, filed 11 May 2020.